Performance of Computed Tomography Angiography (CTA) for the Diagnosis of Hypo-Attenuated Leaflet Thickening (HALT)

Manuel Hein 1,*†, Philipp Breitbart 1, Jan Minners 1, Philipp Blanke 2, Simon Schoechlin 3, Christopher Schlett 3,†, Tobias Krauss 3, Martin Soschynski 3, Franz-Josef Neumann 1 and Philipp Ruile 1

1 Department of Cardiology & Angiology II, University Heart Center Freiburg, 79106 Freiburg, Germany; philipp.breitbart@uniklinik-freiburg.de (P.B.); jan.minners@uniklinik-freiburg.de (J.M.); simon.schoechlin@uniklinik-freiburg.de (S.S.); franz-josef.neumann@uniklinik-freiburg.de (F-J.N.); philipp.ruile@uniklinik-freiburg.de (P.R.)
2 Department of Radiology, St. Paul’s Hospital, University of British Columbia, Vancouver, BC V6Z1Y6, Canada; phil.blanke@gmail.com
3 Department of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; christopher.schlett@uniklinik-freiburg.de (C.S.); tobias.krauss@uniklinik-freiburg.de (T.K.); martin.soschynski@uniklinik-freiburg.de (M.S.)
* Correspondence: manuel.hein@uniklinik-freiburg.de

Abstract: (1) Background: Early hypo-attenuated leaflet thickening (HALT) is diagnosed by computed tomography angiography (CTA) in approximately 15% of patients undergoing transcatheter aortic valve replacement (TAVR). We sought to investigate the diagnostic performance of CTA for the diagnosis of HALT, focusing on timing data assessment within the cardiac cycle. (2) Methods: The study enrolled 50 patients with and 50 without HALT with available post-TAVR-CTA. The primary objective was to compare the diagnostic performance of CTA readings at specific intervals and time points during the cardiac cycle (entire systole, entire diastole, end-systole, and mid-diastole) versus gold standard (consensus reading by two observers based on multiphase full cardiac cycle data sets). (3) Results: 100 CTAs were independently analysed by two observers blinded to clinical characteristics of the study population and the results from the gold standard reading. Sensitivity and specificity for the diagnosis of HALT were 84%/94% in systole, 87%/92% in diastole, 78%/95% at end-systole, and 80%/94% at mid-diastole. End-systole had the highest positive predictive value (0.88) and positive likelihood ratio (36). Cohen’s kappa for interobserver reliability was 0.715 in systole, 0.578 in diastole, 0.650 at end-systole, and 0.517 at mid-diastole. (4) Conclusion: Limiting CTA reading to distinct intervals or time points during the cardiac cycle has good specificity but lowers sensitivity. For a reliable diagnosis of HALT, data sets from a multiphase CTA covering the entire cardiac cycle should be analysed. A double reader approach would be desirable in further studies investigating HALT.

Keywords: TAVR; TAVI; hypo-attenuated leaflet thickening; leaflet thrombosis; post-TAVR-CTA; computed tomography

1. Introduction

Transcatheter aortic valve replacement (TAVR) is the current standard therapy for severe symptomatic aortic stenosis in patients with increased perioperative risk [1–3]. Recent studies described early hypo-attenuated leaflet thickening (HALT) or leaflet restriction in post-TAVR computed tomography angiography (CTA) with a prevalence ranging from 4% to 40% [4–9]. On the one hand, previous studies on medium-term outcomes demonstrated no impact on mortality or stroke [4,5,7,8,10,11]. On the other hand, HALT leads to valve deterioration, at least in some patients [6,8,12], and might be associated with valve degeneration [13].

Besides varying the time periods from intervention to CTA, the discrepancy in prevalence might be caused by using diverse CTA protocols covering either single parts or the
entire cardiac cycle [4,5,10]. A standardized approach to CT data acquisition and interpretation may facilitate the comparability of findings across studies and may help to reduce the applied radiation dose. The Society of Cardiovascular Computed Tomography (SCCT) recommends full multiphase imaging covering the complete cardiac cycle [14]. As the TAVR procedure is progressively applied to younger and lower-risk patients, limiting cardiac cycle coverage may be desirable if there are concerns about radiation exposure.

Therefore, we hypothesized that for the detection of HALT, investigating specific intervals and time points has comparable diagnostic results compared to the assessment of the entire cardiac cycle. In addition, we compared a single versus a two observer evaluation.

2. Materials and Methods

Study population. This observational single-center cohort study was approved by the local institutional review board and complies with the Declaration of Helsinki. The study includes patients with post-TAVR-CTA between 2012 and 2017, when routine CTA was part of the clinical setup post TAVR in our hospital. Clinical reasons for not performing CTAs included renal insufficiency, frailty, and others [5]. Included valve types were the following commercially available balloon- or self-expandable prosthetic valves: SAPIEN XT, SAPIEN 3 (both Edwards Lifesciences, Irvine, CA, USA), CoreValve, Evolut R (both Medtronic, Minneapolis, MN, USA).

HALT was defined as a hypo-attenuated thickening of one or more leaflets visible in at least two different projections and two different reconstruction time points with or without restricted motion, adapted to the definition of SCCT [12]. HALT is characterized as the thickening of the leaflets with a meniscal shape within the long-axis projection view at the center of the cusp, starting at the leaflet’s base [12]. The diagnosis was established by the consensus reading of two experienced observers (P.R. and T.K.) based on complete cardiac cycle analysis, considered the “gold standard”.

CT scan protocol. The CTAs were performed on a 2nd generation dual-source CT scanner (Somatom Definition Flash, Siemens Healthcare, Forchheim, Germany). The post-TAVR-CTA-protocol comprised a contrast-enhanced retrospective ECG-gated CTA-data acquisition of the aortic root in a craniocaudal direction with a temporal resolution of 75 ms without ECG-gated dose modulation to cover the entire RR-interval. The Siemens “Care kV” and “Care Dose” options were used. 50 mL iodinated contrast agent (Imeron 400, Bracco, Konstanz, Germany) was administered at a flow rate of 4 mL/s. A bolus tracking technique with a region of interest placed in the left atrium was used. All CTA images were reconstructed at 50 ms steps throughout the cardiac cycle with a slice thickness of 1 mm, an increment of 0.8 mm, and a stent-specific reconstruction kernel (B46f). Those multiphase data sets were either fully reconstructed, at systole, at diastole, or at single systolic or diastolic time points to simulate image data of retrospective multiphase scan, a (pulsed) prospective scan, or a high pitch scan, respectively.

Image analysis. Image analysis was conducted with a dedicated post-processing workstation (Syngo Multimodality Workplace, Siemens Healthcare, Forchheim, Germany) using multiplanar reformations. Different phases of the cardiac cycle were evaluated regarding the capability to identify HALT by comparing them to the gold standard of HALT diagnosis.

For the recent investigation, fifty anonymized patients with HALT plus fifty without HALT were selected using SPSS random selection. Two blinded observers (M.H. and M.S.) with CT-angiographic experience of more than 1000 CTAs re-evaluated the selected 100 data sets in blinded single and consensus reading. Systole and diastole from each patient were evaluated separately and randomly. Both observers were unaware of the number of patients with positive HALT-finding in the data set.

Mid-diastole was defined as 70 to 75% of the cardiac cycle according to the diastolic heart volume curve in the syngo. via software (Siemens Healthineers, Erlangen, Germany). End-systole was defined by the cardiac cycle curve. Single time points of mid-diastole and end-systole and separate phases of entire systole and diastole were anonymized and
separately stored (P.R.). HALT in single time-point examination was diagnosed in only one reconstruction time point. The resultant four data sets were then separately evaluated (M.H. and M.S.) in random order. Each analysis was blinded from the results of the other cardiac cycle phase. First, all end-systolic and mid-diastolic data sets were analysed in separate sessions, followed by systole/diastole data sets again in separate sessions.

Image quality was assessed on a scale of 0 to 3, with 0 reflecting the worst (non-diagnostic) image quality. One was defined as worse than standard quality. Two was standard quality with a clear contrast between prosthetic valve leaflets and blood volume. Three was better than average quality with perfect contrast between prosthetic valve leaflet and blood volume. Image quality in Table 1 was calculated as a rounded mean of reported image quality of both observers (M.S., M.H.).

**Table 1.** Baseline characteristics of patients without and with HALT.

|                          | All Patients (n = 100) | Without HALT (n = 50) | With HALT (n = 50) | p-Value |
|--------------------------|------------------------|-----------------------|--------------------|---------|
| Age                      | 81.5 ± 5.5             | 80.1 ± 5.4            | 82.2 ± 5.5         | 0.185   |
| Gender                   |                        |                       |                    |         |
| Male                     | 37 (37.0)              | 16 (32.0)             | 21 (42.0)          | 0.400   |
| Female                   | 63 (63.0)              | 34 (68.0)             | 29 (58.0)          |         |
| BMI (kg/m²)              | 27.1 ± 4.3             | 27.3 ± 4.7            | 27.0 ± 3.8         | 0.809   |
| Creatinine-Clearance (mL/min) | 54.7 ± 17.3            | 55.5 ± 18.6           | 53.9 ± 16.1        | 0.648   |
| LV-EF (%)                | 50.0 (8.3)             | 51.5 (8.1)            | 49.1 (8.4)         | 0.162   |
| Atrial fibrillation      | 31 (31.0)              | 20 (40.0)             | 11 (22.0)          | 0.083   |
| Mitral regurgitation     |                        |                       |                    |         |
| None/mild                | 76 (76.0)              | 37 (74.0)             | 39 (78.0)          | 0.591   |
| Moderate                 | 20 (20.0)              | 10 (20.0)             | 10 (20.0)          |         |
| Severe                   | 4 (4.0)                | 3 (6.0)               | 1 (2.0)            |         |
| Tricuspid regurgitation  |                        |                       |                    |         |
| None/mild                | 90 (90)                | 42 (84)               | 48 (96)            | 0.092   |
| Moderate                 | 10 (10)                | 8 (16)                | 2 (4)              |         |
| Heart rate at the time of CT | 54.7 ± 17.3            | 55.8 ± 18.6           | 53.9 ± 16.1        | 0.440   |
| Tube voltage (kV)        | 102.8 ± 9.9            | 103.2 ± 10.2          | 100.0 ± 9.9        | 0.835   |
| Tube current (mAs)       | 307.7 ± 51.1           | 302.0 ± 49.4          | 307.7 ± 52.9       | 0.605   |
| Effective Dose (mSv)     | 9.8 ± 5.1              | 10.2 ± 10.2           | 9.5 ± 5.1          | 0.336   |
| Prosthesis size          |                        |                       |                    |         |
| Small (23 mm)            | 33 (34.7)              | 18 (36.0)             | 15 (33.3)          | 0.867   |
| Medium (25–27 mm)        | 39 (41.1)              | 21 (42.0)             | 18 (40.0)          |         |
| Large (29–31 mm)         | 23 (24.2)              | 11 (22.0)             | 12 (26.7)          |         |
| Prosthesis type          |                        |                       |                    | 1.000   |
| S3/XT                    | 86 (86.0)              | 43 (86.0)             | 43(86.0)           |         |
| CoreValve/EvoluteR       | 14 (14.0)              | 7 (14.0)              | 7 (14.0)           |         |
| PVL at time of CTA (TTE) |                        |                       |                    | 1.000   |
| None/Trace               | 81 (81.0)              | 40 (80.0)             | 41 (81.0)          |         |
| Mild                     | 19 (19.0)              | 10 (20.0)             | 9 (18.0)           |         |
| Moderate                 | 0                      | 0                     | 0                  | 0.010   |
| Visual Image Quality     |                        |                       |                    |         |
| 0                        | 1 (1.0)                | 1 (2.0)               | 0 (0.0)            |         |
| 1                        | 10 (10.0)              | 6 (12.0)              | 4 (8.0)            |         |
| 2                        | 51 (51.0)              | 32 (64.0)             | 19 (38.0)          |         |
| 3                        | 38 (38.0)              | 11 (22.0)             | 27 (54.0)          |         |

HALT: hypo-attenuated leaflet thickening. Values are mean ± SD, median [interquartile range], or n (%). BMI = body mass index. LV-EF: Left ventricular ejection fraction. PVL: Paravalvular leakage. TTE: Transthoracic echocardiogram. mAs: milliampere-second. kV: kilovoltage. Image quality was graded in consensus as follows: 0 = very poor image quality, 1 = poor, 2 = good, 3 = very good.

**Statistical analysis.** All statistical analyses were performed using SPSS-software (SPSS-version 23.0, Chicago, IL, USA). Continuous variables are reported as mean ± standard deviation, ordinal variables as median (interquartile range), and categorical data as numbers (percentages). Kolmogorov-Smirnov test was used to test for Gaussian distribution. For comparison between groups, unpaired Student’s t-test or Mann-Whitney U-test were used if appropriate. Differences in categorical variables were tested using the Pearson’s χ²-test or Fisher’s test depending on sample size. Sensitivity, specificity, negative, and...
positive predictive value (NPV and PPV), negative and positive likelihood ratios, accuracy, and Cohens Kappa were calculated to compare the diagnostic value of each cardiac time point/phase of CTA images. McNemar test was used to compare results of different readers and consensus reading. NPV and PPV for HALT-Finding were calculated with an estimated prevalence of 15.9% [13]. Paired Wilcoxon rank-sum was used to compare image quality between different phases. Variables with \( p < 0.10 \) at baseline as well as mitral valve regurgitation were assessed regarding their influence on HALT finding by logistic regression. Mitral valve regurgitation was added because of possible difficulties regarding the timing of image acquisition after contrast administration resulting in reduced image quality. As heart rate, ejection fraction, tricuspid/mitral valvular regurgitation (grade 0–4), and atrial fibrillation might have influenced image quality, the correlation between those factors and image quality or HALT diagnosis was assessed by using multiple regression.

3. Results

3.1. Patient Characteristics

Between 2012 and 2017, 761 patients with the above-described valves received a post-TAVR-CTA. In 105 of these patients, HALT was diagnosed. The randomly selected 100 CTA studies, 50 with and 50 without HALT, were acquired at a median of 5 days [IQR 4;5] after TAVR. Twenty patients with HALT revealed restricted motion, whereas, in the remaining patients, the motion was unaffected.

Baseline characteristics of the study population are shown in Table 1. The two groups were comparable regarding clinical baseline characteristics with a trend towards a lower prevalence of atrial fibrillation in patients with HALT (\( p = 0.083 \)). Better image quality was found in the group with HALT (\( p = 0.010 \)), whereas heart rate at the time of the CT was comparable between both groups (\( p = 0.440 \)). Regarding echocardiographic parameters, there was a tendency towards fewer patients with moderate tricuspid regurgitation in the HALT group (\( p = 0.092 \)).

3.2. Sensitivity and Specificity of Various Cardiac Cycle Phases and Single Time Points

Sensitivity and specificity for the diagnosis of HALT were 84%/94% in the entire systole and 87%/92% in the entire diastole, respectively. Positive Likelihood ratios were higher than 10 in all parts of the cardiac cycle; however, negative likelihood ratios were above 0.10 (Table 2).

Regarding interpretation limited to single time points, sensitivity and specificity were 78%/95% at end-systole and 80%/94% at mid-diastole, respectively. End-systole had the highest positive predictive value (0.88) and positive likelihood ratio (36). The results of the HALT analysis of every single observer and consensus reading of each analysed cardiac cycle phase, along with each time point, are shown in Table 2.

3.3. Interobserver Reliability

Highest interobserver reliability was achieved in systole with a Cohens kappa of 0.715 (\( p < 0.001 \)) for entire systole and 0.650 (\( p < 0.001 \)) for end-systole.

In diastole, Cohens kappa for mid-diastole was 0.517 (\( p < 0.001 \)) and 0.578 (\( p < 0.001 \)) for entire diastole. Consensus reading in systole or diastole improved especially negative likelihood ratios (Table 2). Examples of HALT found in any cardiac phase or time point and of HALT missed in single observer investigation are shown in Figure 1.
Table 2. Comparison of single observer diagnosis of HALT in different phases of the cardiac cycle with full cardiac cycle consensus reading.

|                | Diastole          | Systole          | Consensus Entire Diastole | Consensus Entire Systole | Observer A End-Systole | Observer B End-Systole | Observer B Entire Systole |
|----------------|-------------------|------------------|---------------------------|--------------------------|------------------------|------------------------|--------------------------|
| **Observer A** | Mid-Diastole      | Entire Diastole  | Mid-Diastole              | Entire Diastole          | End-Systole            | End-Systole            | Entire Systole            |
| True positive  | 38                | 42               | 32                        | 42                       | 38                     | 42                     | 36                       |
| True negative  | 46                | 45               | 47                        | 47                       | 49                     | 47                     | 46                       |
| False positive | 4                 | 5                | 3                         | 3                        | 1                      | 3                      | 1                        |
| False negative | 12                | 8                | 18                        | 8                        | 12                     | 12                     | 14                       |
| % Accuracy     | 0.84              | 0.87             | 0.79                      | 0.89                     | 0.87                   | 0.90                   | 0.81                     |
| % Sensitivity  | 0.76              | 0.84             | 0.64                      | 0.84                     | 0.80                   | 0.87                   | 0.72                     |
| PPV            | 0.64              | 0.61             | 0.67                      | 0.73                     | 0.71                   | 0.67                   | 0.66                     |
| NPV            | 0.63              | 0.59             | 0.67                      | 0.65                     | 0.65                   | 0.61                   | 0.66                     |
| PLR            | 9.5               | 8.2              | 10.7                      | 14.0                     | 13.3                   | 10.7                   | 12.0                     |
| NLR            | 0.26              | 0.18             | 0.38                      | 0.17                     | 0.21                   | 0.14                   | 0.30                     |

HALT = hypo-attenuated leaflet thickening, PPV = positive predictive value, NPV = negative predictive value, PLR = positive likelihood ratio, NLR = negative likelihood ratio.
In univariate analysis, atrial fibrillation (OR 2.364 [0.984;5.677], \( p = 0.054 \)) and mitral regurgitation grading (OR 1.740 [0.910;3.325], \( p = 0.094 \)) tended to be associated with inconsistent HALT findings by both single observers. Only observer reported image quality was associated with consistent HALT finding in univariate and multivariate analysis (OR 2.640 [1.355;5.131], \( p = 0.004 \) and OR 3.277 [1.459;7.358]; \( p = 0.004 \), respectively). Factors influencing image quality are summarized in Table 3.

Table 3. Linear regression of factors influencing image quality.

|                          | Heartrate | Ejection Fraction | Mitral Regurgitation | Tricuspid Regurgitation |
|--------------------------|-----------|-------------------|----------------------|------------------------|
|                          | Standardized Beta | \( p \)  | Standardized Beta | \( p \) | Standardized Beta | \( p \) | Standardized Beta | \( p \) |
| Mid-diastole             | −0.40     | \(<0.001\)        | −0.12                | 0.22                   | 0.13                  | 0.194                | 0.11                  | 0.28                  |
| entire diastole          | −0.32     | 0.002             | −0.10                | 0.32                   | 0.14                  | 0.164                | 0.075                 | 0.47                  |
| end-systole              | −0.07     | 0.54              | −0.127               | 0.21                   | 0.043                 | 0.67                 | 0.08                  | 0.44                  |
| entire systole           | −0.06     | 0.55              | 0.73                 | 0.47                   | 0.02                  | 0.81                 | 0.07                  | 0.49                  |

4. Discussion

We report two main findings: First, reducing the CT protocol for diagnosing HALT to distinct phases or single time points of the cardiac cycle is associated with good specificity but lower sensitivity. Second, for a reliable diagnosis of HALT, acquiring images of the entire cardiac cycle and a double reader consensus approach is desirable.

Recent studies described HALT as a common phenomenon with a prevalence between 4–40\% after TAVR [4,6,9,10]. Its long-term clinical relevance remains controversial, but HALT has been suspected to be associated with TIA, valve dysfunction, and valve degeneration [6,7,11–13,15]. So far, there is no evidence that routinely performed post-TAVR CTA would influence prognosis in cohorts of such old patients. As HALT leads to valve deterioration in some patients and as it can be treated by anticoagulation therapy, post-TAVR scans are of worth in clinical practice when there are echocardiographic signs of valve dysfunction [6,8,12,16]. Further, the TAVR procedure is expanding to low-risk cohorts and younger patients [1,17]. Especially, younger patients show a higher risk of
valve degeneration after surgical valve replacement with bioprosthetic valves [7,12,18].
To avoid repeat valve interventions, especially in those with longer life expectancy, po-
tential factors influencing durability should be investigated with reliable, standardized
diagnostics with the lowest radiation exposure possible. From coronary CTA, we know
that dose reduction is possible using different acquisition techniques. The effective dose of
a high pitch spiral scan is about 13% of the dose of a multiphase retrospective scan, and
the effective dose of a prospective (pulsed) scan is about 28% of a multiphase retrospective
scan [19]. However, dose reduction should not lead to a decrease in diagnostic sensitivity.
This is crucial for further investigation of the phenomenon of HALT and to draw confident
conclusions regarding prevalence, natural history, and treatment strategies. In this line,
the latest recommendations suggest image acquisition of the complete cardiac cycle in
post-TAVR-CTA [14]. To the best of our knowledge, there is no published scientific evidence
comparing any approaches. Furthermore, it is unclear whether a single observer approach,
as commonly performed, is sufficient in this setting.

We report that limiting the CT scan evaluation to distinct phases of the cardiac cycle,
although associated with good specificities and positive likelihood ratios, goes along with only
moderate sensitivities. We, therefore, consider limiting CT scanning to distinct cardiac
phases in general—in line with the current SCCT recommendations—as not advisable. In
the present study, the gold standard diagnosis was established by consensus reading by two
experienced observers. To us, this was the most accurate way to assess even small findings
and might be the most appropriate way to diagnose HALT in clinical trials. However, even
by defining consensus reading as the gold standard, this approach might not be immune
against misclassification, and itself might have influenced the results. In daily routine, a
single observer might be sufficient to detect HALT with concomitant leaflet restriction, as
in those cases, thrombus volumes are often large. Therefore, some trials suggest using
HALT with more than 50% leaflet involvement as study endpoints [20]. However, our data
suggest that (even with experienced readers) a single observer approach may be insufficient
if small thrombotic volumes are investigated.

On the one hand, our data suggest as a rule of thumb: “If one observer sees a thrombus,
there usually is one”. On the other hand, if there is only one observer or a CT scan
with incomplete coverage of the cardiac cycle, HALT cannot be excluded. Therefore,
future studies investigating the possibility of reducing radiation in post-TAVR CTAs to
distinct cardiac phases by techniques like pulsing or even high pitch acquisition need to be
planned with caution when any HALT extend is investigated. In clinical practice, extended
masses of HALT might be more relevant. As patients with large HALT are rare, further
(multicenter) studies investigating the sensitivity of limited CTA acquisition in patients
with hemodynamic valve deterioration are desirable.

In our study, image quality was the only independent predictor for HALT. As expected,
image quality in diastole was better than in systole [21,22]. Heart rate, in turn, was
confirmed to influence image quality in diastole [23]. Other factors such as atrial fibrillation,
ejection fraction, or valve regurgitation were not associated with image quality in any phase
of the cardiac cycle.

Computed tomographic findings of suspected leaflet thrombosis after TAVR vary
substantially, resulting in several definitions, including hypo-attenuating leaflet thickening
(HALT), hypo-attenuation affecting motion (HAM), and others [5,6,11,16]. In the current
study, HALT is defined comprehensively as hypo-attenuated leaflet thickening independent
of motion-related factors or the number of reconstruction time points, thereby covering
both HALT and HAM [16].

5. Conclusions

To obtain high sensitivity for the diagnosis of early HALT after TAVR, a CT protocol
covering the entire cardiac cycle as suggested in current recommendations is advisable. A
double reader approach would be desirable in further studies investigating HALT.
6. Limitations

Our study is small, and though issued from a center with long-standing experience in cardiac imaging, results require external validation. We did not perform repeat CTAs using different image acquisition techniques in each patient (retrospective full multiphase vs. prospective pulsed imaging vs. high pitch imaging), but used retrospective multiphase scans as the basis for comparison. Therefore, direct comparison of radiation exposure is not possible. Issues of standardizing diagnostics such as the timing of CTA concerning the TAVR procedure have to be addressed in further studies. Finally, the gold standard for diagnosing HALT was based on a full cardiac cycle CTA protocol with two readers. Although this appears adequate compared to less extensive protocols, alternate modalities may prove more accurate in the future. Upcoming photon-counting CTs might reduce metal artifacts to facilitate automated algorithms for HALT detection. We did not differ between various extents of HALT, as only a few patients showed large findings directly after TAVR. This should be addressed in further studies investigating patients who qualify for symptomatic hemodynamic valve deterioration.

Author Contributions: M.H. conceived and designed the research, analysed the images, performed statistical analysis, and drafted the manuscript. P.B. (Philip Breitbart) acquired the data and critically revised the manuscript. J.M. made critical revision of the manuscript for key intellectual content and performed statistical analysis. P.B. (Philipp Blanke) made critical revision of the manuscript for key intellectual content. S.S. performed statistical analysis. C.S. conceived and designed the research. T.K. conceived and designed the research and acquired the data. M.S. conceived and designed the research and analysed the images. F.-J.N. conceived and designed the research and critically revised the manuscript for key intellectual content. P.R. conceived and designed the research and acquired the data. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Ethics Committee of Albert-Ludwigs University (EK-Nr.:472/12, 6 December 2012).

Informed Consent Statement: Patient consent was waived due to an anonymised data set.

Data Availability Statement: Transferring data to third parties is not included in the ethics statement. Please contact the corresponding author for submitting a request to the ethics committee, if desired.

Conflicts of Interest: P. Blanke, consultant for Edwards Lifesciences and Circle Cardiovascular Imaging; provides CT core lab services for Edwards Lifesciences, Medtronic, Neovasc, and Tendyne Holdings, for which he receives no direct compensation. F.-J. Neumann: Grants to institution from Boston Scientific, Biotronik, Medtronic, Edwards Lifescience, Abbott Vascular. M. Hein, P. Breitbart, S. Schoechlin, J. Minners, C. L. Schlett, T. Krauß, M. Soschynski, Philipp Ruile have nothing to declare.

References

1. Mack, M.J.; Leon, M.B.; Smith, C.R.; Miller, D.C.; Moses, J.W.; Tuzcu, E.M.; Webb, J.G.; Douglas, P.S.; Anderson, W.N.; Blackstone, E.H.; et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): A randomised controlled trial. Lancet 2015, 385, 2477–2484. [CrossRef]
2. Leon, M.B.; Smith, C.R.; Mack, M.J.; Makkar, R.R.; Svensson, L.G.; Kodali, S.K.; Thourani, V.H.; Tuzcu, E.M.; Miller, D.C.; Herrmann, H.C.; et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2016, 374, 1609–1620. [CrossRef] [PubMed]
3. Adams, D.H.; Popma, J.J.; Reardon, M.J.; Yakubov, S.J.; Coselli, J.S.; Deeb, G.M.; Gleason, T.G.; Buchbinder, M.; Hermiller, J.; Kleiman, N.S.; et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. N. Engl. J. Med. 2014, 370, 1790–1798. [CrossRef] [PubMed]
4. Makkar, R.R.; Fontana, G.; Jilaihawi, H.; Chakravarty, T.; Kofoed, K.F.; de Backer, O.; Asch, F.M.; Ruiz, C.E.; Olsen, N.T.; Trento, A.; et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N. Engl. J. Med. 2015, 373, 2015–2024. [CrossRef]
5. Pache, G.; Schoechlin, S.; Blanke, P.; Dorfs, S.; Jander, N.; Arepalli, C.D.; Gick, M.; Buettner, H.-J.; Leipsic, J.; Langer, M.; et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur. Heart J. 2016, 37, 2263–2271. [CrossRef]
6. Chakravarty, T.; Søndergaard, L.; Friedman, J.; De Backer, O.; Berman, D.; Kofoed, K.F.; Jilaihawi, H.; Shiota, T.; Abramowitz, Y.; Jørgensen, T.H.; et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: An observational study. *Lancet* 2017, 389, 2383–2392. [CrossRef]

7. Ruile, P.; Jander, N.; Blanke, P.; Schoechlin, S.; Reinöhl, J.; Gick, M.; Rothe, J.; Langer, M.; Leipsic, J.; Buettner, H.-J.; et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. *Clin. Res. Cardiol.* 2017, 106, 85–95. [CrossRef]

8. Hansson, N.C.; Grove, E.L.; Andersen, H.R.; Leipsic, J.; Mathiassen, O.N.; Jensen, J.M.; Jensen, K.T.; Blanke, P.; Leetmaa, T.; Tung, M.; et al. Transcatheter Aortic Valve Replacement: Incidence, Predisposing Factors, and Clinical Implications. *J. Am. Coll. Cardiol.* 2016, 68, 2059–2069. [CrossRef]

9. Leetmaa, T.; Hansson, N.C.; Leipsic, J.; Poulsen, S.H.; Andersen, H.R.; Jensen, J.M.; Webb, J.; Blanke, P.; Tung, M.; et al. Early Aortic Transcatheter Heart Valve Thrombosis: Diagnostic Value of Contrast-Enhanced Multidetector Computed Tomography. *Circ. Cardiovasc. Interv.* 2015, 8, e001596. [CrossRef]

10. Yangagisawa, R.; Hayashida, K.; Yamada, Y.; Tanaka, M.; Yashima, F.; Inohara, T.; Arai, T.; Kawakami, T.; Maekawa, Y.; Tsuruta, H.; et al. Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR. *JACC Cardiovasc. Imaging* 2016, 12, e007349. [CrossRef]

11. Vollema, E.M.; Kong, W.K.; Katsanos, S.; Kamperidis, V.; van Rosendael, P.J.; van der Kley, F.; de Weger, A.; Ajmone Marsan, N.; Delgado, V.; Bax, J.J. Transcatheter aortic valve thrombosis: The relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke. *Europ. J. Heart Fail.* 2017, 18, 1207–1217. [CrossRef] [PubMed]

12. Hein, M.; Minners, J.; Jander, N.; Breitbart, P.; Schoechlin, S.; Gick, M.; Pache, G.; Neumann, F.-J.; Ruile, P. Haemodynamic prosthetic valve performance in patients with early leaflet thrombosis after transcatheter aortic valve implantation. *Clin. Res. Cardiol.* 2019, 108, 1017–1024. [CrossRef] [PubMed]

13. Sellers, S.L.; Turner, C.T.; Sathananthan, J.; Cartlidge, T.R.G.; Sin, F.; Bouchareb, R.; Mooney, J.; Nørgaard, B.L.; Bax, J.J.; Bernatchez, P.N.; et al. Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration. *JACC Cardiovasc. Imaging* 2019, 12, 135–145. [CrossRef] [PubMed]

14. Blanke, P.; Weir-McCall Jonathan, R.; Achenbach, S.; Delgado, V.; Hausleiter, J.; Jilaihawi, H.; Marwan, M.; Nørgaard, B.L.; Piazza, N.; Schoenhagen, P.; et al. Computed Tomography Imaging in the Context of Transcatheter Aortic Valve Implantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR). *JACC Cardiovasc. Imaging* 2019, 12, 1–24. [CrossRef]

15. Ruile, P.; Minners, J.; Breitbart, P.; Schoechlin, S.; Gick, M.; Fache, G.; Neumann, F.-J.; Hein, M. Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement. *JACC Cardiovasc. Interv.* 2018, 11, 1164–1171. [CrossRef]

16. Sondergaard, L.; De Backer, O.; Kofoed, K.F.; Jilaihawi, H.; Fuchs, A.; Chakravarty, T.; Kashif, M.; Kazuno, Y.; Kawamori, H.; Maeno, Y.; et al. Natural History of Subclinical Leaflet Thrombosis Affecting Motion in Bioprosthetic Aortic Valves. Available online: https://academic.oup.com/eurheartj/article-abstract/doi/10.1093/eurheartj/ehx369/3924514/Natural-history-of-subclinical-leaflet-thrombosis (accessed on 6 July 2017).

17. Mack, M.J.; Leon, M.B.; Thourani, V.H.; Makkar, R.; Kodali, S.K.; Russo, M.; Kapadia, S.R.; Malaisrie, S.C.; Cohen, D.J.; Pibarot, P.; et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N. Engl. J. Med.* 2019, 380, 1695–1705. [CrossRef]

18. Banbury, M.K.; Cosgrove, D.M.; White, J.A.; Blackstone, E.H.; Frater, R.W.M.; Okies, J.E. Age and valve size effect on the long-term durability of the Carpentier-Edwards aortic pericardial bioprosthesis. *Ann. Thorac. Surg.* 2001, 72, 753–757. [CrossRef]

19. Kosmala, A.; Petritsch, B.; Weng, A.M.; Bley, T.A.; Gassenmaier, T. Radiation dose of coronary CT angiography with a third-generation dual-source CT in a “real-world” patient population. *Eur. Radiol.* 2019, 29, 4341–4348. [CrossRef]

20. De Backer, O.; Dangas, G.D.; Jilaihawi, H.; Leipsic, J.A.; Terkelsen, C.J.; Makkar, R.; Kini, A.S.; Veen, K.T.; Abdel-Wahab, M.; Kim, W.-K.; et al. Reduced Leaflet Motion at Transcatheter Aortic Valve Replacement. *N. Engl. J. Med.* 2020, 382, 130–139. [CrossRef]

21. Kopp, A.F.; Schroeder, S.; Kuettner, A.; Heuschmid, M.; Georg, C.; Ohnesorge, B.; Kuzo, R.; Clausen, C.D. Coronary Arteries: Retrospectively ECG-gated Multi-Detector Row CT Angiography with Selective Optimization of the Image Reconstruction Window. *Radiology* 2001, 221, 683–688. [CrossRef]

22. Weustink, A.C.; Mollet, N.R.; Pugliese, F.; Meijboom, W.B.; Nieman, K.; Heijenbrok-Kal, M.H.; Flohr, T.G.; Neefjes, L.A.E.; Cademartiri, F.; de Feyter, P.J.; et al. Optimal Electrocardiographic Pulsing Windows and Heart Rate: Effect on Image Quality and Radiation Exposure at Dual-Source Coronary CT Angiography. *Radiology* 2008, 248, 792–798. [CrossRef] [PubMed]

23. Achenbach, S.; Manolopoulos, M.; Schuhbäck, A.; Ropers, D.; Rixe, J.; Schneider, C.; Krombach, G.A.; Uder, M.; Hamm, C.; Daniel, W.G.; et al. Influence of heart rate and phase of the cardiac cycle on the occurrence of motion artifact in dual-source CT angiography of the coronary arteries. *J. Cardiovasc. Comput. Tomogr.* 2012, 6, 91–98. [CrossRef] [PubMed]